Author

L. Quevedo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

I. Varela· 2 shared A. Agraz-Doblas· 1 shared A. Astudillo· 1 shared A. Ramiro· 1 shared A. V. Marin· 1 shared B. Casar· 1 shared B. Monterde· 1 shared C. Morales Torres· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Varela

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, and enhances the viral infection of Burkitt lymphoma cells

E. Molina, L. Garcia-Gutierrez, V. Junco, M. Perez-Olivares, V. G de Yebenes, R. Blanco, L. Quevedo, J. C. Acosta, A. V. Marin, D. Ulgiati, R. Merino, I. Varela, J. R. Regueiro, I. Moreno de Alboran, A. Ramiro, J. Leon

This paper identifies CR2/CD21 as a direct target of MYC and shows that MYC enhances EBV infection in Burkitt lymphoma cells.

bioRxiv · Dec 28, 2022 · PreprintCancer Biology

ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to PARP inhibition in lung cancer

T. Moreno, L. Gonzalez-Silva, B. Monterde, I. Betancor-Fernandez, C. Revilla, A. Agraz-Doblas, J. Freire, P. Isidro, L. Quevedo, S. Montes-Moreno, L. Cereceda, A. Astudillo, B. Casar, P. Crespo, C. Morales Torres, , I. Varela

This study identifies ARID2 deficiency in 20% of lung cancer patients, showing it promotes tumor progression and increases sensitivity to PARP inhibition.

bioRxiv · Jan 10, 2020Cancer Biology